Gyre Therapeutics (GYRE) FCF Margin: 2009-2025
Historic FCF Margin for Gyre Therapeutics (GYRE) over the last 14 years, with Sep 2025 value amounting to 12.98%.
- Gyre Therapeutics' FCF Margin rose 893.00% to 12.98% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.70%, marking a year-over-year increase of 482.00%. This contributed to the annual value of -5.63% for FY2024, which is 2095.00% down from last year.
- According to the latest figures from Q3 2025, Gyre Therapeutics' FCF Margin is 12.98%, which was up 85.51% from 7.00% recorded in Q2 2025.
- Gyre Therapeutics' FCF Margin's 5-year high stood at 41.67% during Q4 2022, with a 5-year trough of -1,777.65% in Q2 2021.
- Over the past 3 years, Gyre Therapeutics' median FCF Margin value was 7.00% (recorded in 2025), while the average stood at 5.32%.
- As far as peak fluctuations go, Gyre Therapeutics' FCF Margin plummeted by 163,089bps in 2021, and later soared by 155,243bps in 2023.
- Over the past 5 years, Gyre Therapeutics' FCF Margin (Quarterly) stood at -724.43% in 2021, then soared by 76,610bps to 41.67% in 2022, then plummeted by 3,786bps to 3.82% in 2023, then slumped by 1,348bps to -9.66% in 2024, then soared by 893bps to 12.98% in 2025.
- Its FCF Margin stands at 12.98% for Q3 2025, versus 7.00% for Q2 2025 and -1.14% for Q1 2025.